Skip to main content

Open Access 16.05.2024 | Original Research

florio® HAEMO: A Longitudinal Survey of Patient Preference, Adherence and Wearable Functionality in Central Europe

verfasst von: Ester Zapotocka, Angelika Batorova, Ernest Bilic, Ana Boban, Carmen Escuriola Ettingshausen, Barbara Faganel Kotnik, Radomira Hrdlickova, Pawel Laguna, Jan Máchal, Laszlo Nemes, Irena Preloznik Zupan, Gediminas Puras, Marianna Zombori

Erschienen in: Advances in Therapy

Abstract

Introduction

florio® HAEMO is a hemophilia treatment monitoring application (app) offering activity tracking and wearable device connectivity. Its use might support everyday activities for people with hemophilia. The aim of this study was to evaluate user satisfaction, long-term usage and the impact on data entry when pairing a wearable with a hemophilia monitoring app.

Methods

This is a follow-up of a two-part user survey conducted in Central Europe. People with hemophilia and parents/caregivers of children with hemophilia using florio HAEMO and who completed part one were invited to complete a second online questionnaire at least 4 months later.

Results

Fifty participants (83.3%) who completed part one of the survey continued to use the florio HAEMO app and completed part two. Of 14 participants who chose to use the app with a wearable, more than half (57.1%) were aged between 13 and 25 years. Overall, the results demonstrated that florio HAEMO is very easy or rather easy to use, especially for individuals pairing the app with a wearable. Most people using a wearable indicated that florio HAEMO was very or rather important in bringing certainty to daily activities (85.7%). Notably, 14 of 36 (38.9%) non-wearable users indicated that they would prefer to pair the app with a wearable in the future.

Conclusions

Adherence to the florio HAEMO app is maintained over an extended period of use. Pairing the app with a wearable might enable easier access to app features, increase data entry motivation and provide more certainty about daily activities for people with hemophilia.
Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1007/​s12325-024-02872-3.
Key Summary Points
Why carry out this study?
Hemophilia demands continuous management to prevent bleeds, posing economic challenges and a need for innovative management solutions.
The florio® HAEMO app, with activity tracking and wearable support, seeks to improve daily life for patients with hemophilia, potentially easing the disease's burden.
Satisfaction and practical aspects of hemophilia treatment monitoring using the florio HAEMO app are maintained even with long-term experience.
Pairing a wearable device with the florio HAEMO app might support everyday activities for people with hemophilia through easier access to app features and increased motivation for data entry.
What was learned from the study?
Adherence to the florio HAEMO app is maintained over time, and pairing the app with a wearable can make the app easier to use, motivate users to enter data more frequently and provide greater certainty in managing daily activities for people with hemophilia.
The results of this study could encourage the development of more user-friendly and effective treatment monitoring solutions in hemophilia care.

Introduction

The management of hemophilia has seen significant progress in recent years with the introduction of several novel pharmacological treatments, including extended half-life recombinant factors, non-factor therapy and the production of endogenous factors with gene therapy [1]. Yet, despite adequate prophylaxis and advanced treatment options, managing hemophilia continues to disrupt everyday routines and significantly impact the quality of life (QoL) of individuals living with the disease [1]. Routine factor administration also causes scarring and damage to veins, potentially resulting in poor medication adherence [1].
Although most people with hemophilia can participate in and enjoy various physical activities, including contact sports, prophylaxis foreplanning is essential because of a higher risk of bleeding and injury [1]. Furthermore, long-term complications such as joint arthropathy still occur in individuals on prophylaxis treatment, representing a significant source of morbidity [1]. Smartphone hemophilia monitoring applications (apps) have been developed to help people with hemophilia track bleeds, injections and factor supply as well as foreplan their daily physical activities [25]. The latest mobile app, florio® HAEMO (Florio GmbH; https://​www.​florio.​com), can be used with any factor product and has the option to be paired with a wearable device (wearable) [2]. florio HAEMO uses the centralized McMaster population pharmacokinetic (PopPK) database based on Web Accessible Population Pharmacokinetics Service-Hemophilia (WAPPs-Hemo) to securely input PopPK-powered real-time factor level estimations [2, 6]. Knowledge of PopPK estimations in daily life helps people with hemophilia self-manage their treatment, avoid unexpected bleeding episodes and foreplan their daily activities. Wearable technologies in health research, such as fitness trackers, smartwatches, electrocardiogram monitors, blood pressure monitors and biosensors, have offered much potential, with demand increasing in recent years [7, 8]. How the use of wearable technology affects healthcare providers’ decisions and patient behavior remains, as yet, unclear [8]. Moreover, to the best of our knowledge, no data on pairing a wearable with a hemophilia monitoring app have been published to date. Emerging evidence from the literature suggests that using wearables in healthcare can empower individual patients by assisting with diagnosis, behavior change, treatment self-monitoring and management, and QoL parameters such as supporting daily physical activities [9].
Previously, we conducted the first user satisfaction survey of the florio HAEMO app in Central Europe [2]. Users of this hemophilia monitoring app were invited by their treating physician to complete a baseline survey after a median of 3–4 weeks using the app [2]. Initial results from part one of the survey indicated that 89.4% of 66 users were very satisfied or rather satisfied with the florio HAEMO app [2]. In addition, 97.0% of florio HAEMO users reported that the app was very easy or rather easy to use, with 94.0% of users reporting that the app was intuitive to use [2]. During the first part of the survey, participants had the option to test a wearable with the florio HAEMO app, with the aim that it may further assist them in tracking physical activity more precisely, among other benefits [2]. A pre-planned follow-up questionnaire was designed to be completed at least 6 months after the baseline survey [2]. We report the results of the second part of the florio HAEMO app survey, which evaluates additional data on user satisfaction, longer-term adherence and functionality using a wearable with the app. This study aims to evaluate user satisfaction and long-term usage with the florio HAEMO hemophilia monitoring app. In addition, we aimed to determine the impact on data entry in a subgroup of patients who chose to test a wearable paired with the app.

Methods

Study Design

The design of this two-part survey has been previously fully described [2]. After about 24–26 weeks of florio HAEMO usage, participants in the first patient satisfaction questionnaire completed a follow-up questionnaire focusing on long-term usage (approximately 6 months or more) and patient satisfaction with the florio HAEMO app. Wearable functionality was also assessed, and participants > 12 years of age were invited by their physicians to trial a wearable during the second part of the study. Participants could choose to test a loaned Garmin Vivoactive 3 smartwatch or an Apple Watch Series 3 smartwatch for the purposes of this study. Participants could only test a loaned smartwatch. The second online questionnaire consisted of 16 questions about overall satisfaction, ease of use, intuitiveness and type of prophylaxis therapy using a 5-point Likert scale and open-ended questions. Participants were invited by their physicians to complete part two of the survey at least 4 months after starting to use the florio HAEMO app (i.e., 4 months after part one of the survey was completed).
The online survey platform (Typeform™) was administered by Seesame s.r.o (Bratislava, Slovakia) for the follow-up questionnaire (questionnaire 2), as for the first online questionnaire conducted at baseline (questionnaire 1). Responses were collected and analyzed by Seesame s.r.o in compliance with European General Data Protection Regulation 2016/679, local legislations and Ethics Committee approval (University Hospital Bratislava Ethics Committee) in accordance with the Helsinki Declaration of 1964 and its later amendments. All respondents (people with hemophilia and caregivers/parents of people with hemophilia) provided informed consent for partaking in the study and any subsequent publication before completing the two questionnaires as part of the survey initiation. No internet protocol addresses or other identifiable information was stored. The Central European florio HAEMO expert panel interpreted the anonymized results.

Participants

Adults and children with either hemophilia A or B of any severity on regular prophylaxis with any factor concentrate (e.g., plasma-derived or recombinant [r] standard half-life [SHL] or extended half-life [EHL]) participated in this survey. Other hemophilia therapies (e.g., non-factor prophylaxis, on-demand factor treatment, etc.) were not supported by the florio HAEMO app at the time of the survey. A total of 106 people with hemophilia or caregivers of people with hemophilia using florio HAEMO in Central Europe were initially invited to complete the online survey via an electronic link sent by the treating physician. A total of 66 people with hemophilia or caregivers of people with hemophilia using florio HAEMO in Central Europe completed the first online questionnaire as described previously. Participants who completed the baseline questionnaire (questionnaire 1) and continued using florio HAEMO were eligible for inclusion in the follow-up analysis presented herein. Eligible participants were invited to complete the follow-up questionnaire (questionnaire 2) online between 15 June and 16 December 2021.

Statistical Analysis

Results from the second part of the survey are reported using descriptive statistics. No formal statistical testing was performed.

Results

Participants

Of the 66 participants completing the first part of the florio HAEMO survey (questionnaire 1), 50 (75.8%) completed the second part of the survey (questionnaire 2). The respondents of questionnaire 2 represented people with either hemophilia A (n = 43; 86.0%) or hemophilia B (n = 7; 14.0%). Table 1 shows that most respondents (32.0%) were people with hemophilia aged 26–49 years. In questionnaire 2, 14 respondents used a wearable with the florio HAEMO app, 8 (57.1%) of which were people with hemophilia aged between 13 and 25 years. SHL or EHL rFactor VIII (rFVIII) products were the most frequently administered type of prophylaxis (36.0% and 44.0%, respectively) by participants of the survey. A total of 30 respondents (60.0%) had used the florio HAEMO app for at least 7 months, and 20 respondents (40.0%) had used the app for 6 months or less before completing questionnaire 2. An Android operating system was used in conjunction with the florio HAEMO app by most respondents (76.0%), including those using a wearable (92.9%) (Table 1).
Table 1
Demographics and characteristics of respondents
 
Questionnaire 1 respondents
(N = 66)
n (%)
Questionnaire 2 respondents
(N = 50)
n (%)
Respondent
 Person with hemophilia
  
  Total
40 (60.6)
30 (60.0)
   With wearable
 
10
   Without wearable
 
20
 Parent/caregiver of a person with hemophilia
  
  Total
26 (39.4)
20 (40.0)
   With wearable
 
4
   Without wearable
 
16
Age
 Group 1: Parent/caregiver of a person with hemophilia aged ≤ 6 years
  
  Total
8 (12.1)
3 (6.0)
   With wearable
 
0
   Without wearable
 
3
 Group 2: Parent/caregiver of a person with hemophilia aged 7–12 years
  
  Total
15 (22.7)
13 (26.0)
   With wearable
 
0
   Without wearable
 
13
 Group 3: Either a person with hemophilia or parent/caregiver of a person with hemophilia aged 13–25 years
  
  Total
19 (28.8)
15 (30.0)
   With wearable
 
8
   Without wearable
 
7
 Group 4: Person with hemophilia aged 26–49 years
  
  Total
22 (33.3)
16 (32.0)
   With wearable
 
6
   Without wearable
 
10
 Group 5: Person with hemophilia aged ≥ 50 years
  
  Total
2 (3.0)
3 (6.0)
   With wearable
 
0
   Without wearable
 
3
Country of respondent
 Croatia
  
  Total
12 (18.2)
7 (14.0)
   With wearable
 
0
   Without wearable
 
7
 Czech Republic
  
  Total
   With wearable
   Without wearable
26 (39.4)
24 (48.0)
 
7
 
17
 Hungary
  
  Total
9 (13.6)
6 (12.0)
   With wearable
 
5
   Without wearable
 
1
 Poland
  
  Total
6 (9.1)
3 (6.0)
   With wearable
 
0
   Without wearable
 
3
 Slovakia
  
  Total
10 (15.2)
10 (20.0)
2
8
   With wearable
 
   Without wearable
 
 Slovenia
  
  Total
3 (4.5)
0 (0.0)
   With wearable
 
0
   Without wearable
 
0
Education level of the respondent (Person with hemophilia aged 13 years or over or parent/caregiver of a person with hemophilia)
 Not yet finished secondary school:
  
  Total
16 (24.2)
12 (24.0)
   With wearable
 
4
   Without wearable
 
8
 Current student at college/university:
  
  Total
3 (4.5)
4 (8.0)
   With wearable
 
2
   Without wearable
 
2
 Currently in further education:
  
  Total
12 (18.2)
11 (22.0)
   With wearable
 
4
   Without wearable
 
7
 Degree (university or college):
  
  Total
22 (33.3)
17 (34.0)
   With wearable
 
3
   Without wearable
 
14
 Other (finished secondary school but did not enter further education):
  
  Total
13 (19.7)
6 (12.0)
   With wearable
 
1
   Without wearable
 
5
 Type of factor concentrate PPX
pd-FVIII
  
  Total
5 (7.6)
3 (6.0)
   With wearable
 
0
   Without wearable
 
3
 SHL-rFVIII
  
  Total
20 (30.3)
18 (36.0)
6
12
   With wearable
 
   Without wearable
 
 EHL-rFVIII
  
  Total
32 (48.5)
22 (44.0)
   With wearable
 
7
   Without wearable
 
15
 pd-FIX
  
  Total
1 (1.5)
1 (2.0)
0
1
   With wearable
 
   Without wearable
 
 SHL-rFIX
  
  Total
4 (6.1)
3 (6.0)
   With wearable
 
1
   Without wearable
 
2
 EHL-rFIX
  
  Total
4 (6.1)
3 (6.0)
0
3
   With wearable
 
   Without wearable
 
Duration using florio HAEMO
 < 6 months
 
  Total
   With wearable
   Without wearable
2 (4.0)
0
2
 6 months
 
  Total
   With wearable
   Without wearable
18 (36.0)
5
13
 > 6 months
 
  Total
   With wearable
   Without wearable
30 (60.0)
9
21
Operating system used for florio HAEMO
 iOS
  
  Total
15 (22.7)
12 (24.0)
   With wearable
 
1
   Without wearable
 
11
 Android
  
  Total
51 (77.3)
38 (76.0)
   With wearable
 
13
   Without wearable
 
25
EHL extended half-life recombinant, FVIII clotting factor VIII, FIX clotting factor IX, iOS internet operating system, pd plasma-derived, PPX, prophylaxis, r, recombinant, SHL standard half-life recombinant
Parent/caregiver of a person with hemophilia corresponds to completing the online questionnaire only and does not correspond to the caregiver version of florio HAEMO

Overall User Satisfaction, Compliance and Patient Preference

Most respondents (92.0%) remained very satisfied or rather satisfied using the florio HAEMO app throughout this study (Fig. 1). Of the people with hemophilia using a wearable in part 2 of the survey, most indicated that they were very satisfied with florio HAEMO. Most respondents (78.0%) completing questionnaire 2 indicated that they managed to enter all relevant data for all infusions over the past 2 weeks before completing questionnaire 2 (Supplementary Material Figure S1); however, 22.0% reported that they had skipped data entry for at least one infusion. Of the seven respondents (14.0%) on prophylaxis who had experienced pain over the past 2 weeks prior to completion of questionnaire 2, three respondents (42.9%) reported using the modality of florio HAEMO app to enter their pain level compared to four (57.1%) who did not enter their pain level when it was present at least once. Numerically, the use of a wearable indicated a trend for increased data entry. Of the 17 (34.0%) respondents who indicated in the survey they had experienced a breakthrough bleed during the study period, most (82.4%, 14 of 17 users) entered the bleeding episode into the florio HAEMO app. The remaining three respondents who indicated in the survey they had experienced a breakthrough bleed (17.6%) missed inputting data about their bleeding episode into florio HAEMO at least once (Fig. 2). The most frequently used and the least frequently used app function indicated by respondents did not change between the first and second questionnaires, with 90.0% of respondents in questionnaire 2 indicating they used the app to monitor their factor levels and only 2.0% indicating they discussed their florio HAEMO data with their doctor, respectively (Fig. 3).

Ease of Use and Intuitiveness

Florio HAEMO users were asked to assess how easy it was to use the app and how intuitive its features were. Overall, the results provided by responders in questionnaire 2 were similar to those provided in the first questionnaire (Supplementary Material Figure S2). For most responders completing questionnaire 2 (92.0%), florio HAEMO remained very easy or rather easy to use, especially for people with hemophilia using a wearable (Supplementary Material Figure S2). Similarly, 44 of the 50 respondents (88.0%) indicated that the app is very intuitive or rather intuitive to use (Fig. 4). A total of 42 respondents (82.4%) did not experience any difficulties using the app (Fig. 5).

Preference for Wearables and Impact of Florio HAEMO on Daily Activities

When asked how essential the florio HAEMO app was in bringing more certainty to daily activities for people with hemophilia or their parents/caregivers, 34 of 50 responders (68.0%) in questionnaire 2 indicated that the app was very important or rather important to them (Fig. 6). In particular, most people with hemophilia testing a wearable (85.7%) indicated that florio HAEMO was very or rather important in bringing certainty to daily activities. Of the 14 people with hemophilia using florio HAEMO with a wearable, 13 users tested the Garmin Vivoactive 3 smartwatch and 1 user tested the Apple Watch Series 3 smartwatch. A total of ten wearable users (71.4%) indicated that they would strongly prefer or prefer to use a wearable in the future. Notably, of the 36 respondents who had not used a wearable with the florio HAEMO app, 14 (38.9%) indicated that they would also strongly prefer or prefer to use a wearable in the future (Fig. 7).

Discussion

Successful management of chronic diseases such as hemophilia often requires people with the condition to develop self-management skills (i.e., bleed recognition, self-infusion, medicines management, pain and risk management and conceptualization of preventative therapy). In addition, to improve health outcomes, QoL and well-being, people with hemophilia must adhere to their treatment regimen and maintain positive health behaviors from a young age [10]. Recent evidence from the literature suggests that using innovative interventions delivered by telehealth routes, such as mobile apps, can help improve adherence and self-care (e.g., using electronic logs and reminder systems) [2, 11, 12]. In the first part of our survey in Central Europe, we previously reported that the majority of first users of the mobile hemophilia monitoring app, florio HAEMO, found it to be very important or rather important in bringing more certainty to everyday activities for people with hemophilia and/or their caregivers [2]. In the second part of the florio HAEMO survey, 75.7% of participants who completed the first part also completed the follow-up questionnaire after approximately 6 months, indicating a continuously high level of adherence to the florio HAEMO app. Overall, most respondents completing the second questionnaire indicated a high level of satisfaction (92.0%), ease of use (92.0%) and intuitiveness (88.0%) with using the app, consistent with the findings from the first part of our survey. These updated findings support the hypothesis that an efficiently designed hemophilia monitoring app can support the needs of patients with hemophilia on prophylaxis and/or their caregivers with the potential for long-term adherence.
Based on our survey design and the first questionnaire results completed by 66 first-time users of florio HAEMO, we speculated that using a wearable might increase the precision capabilities of florio HAEMO and further support hemophilia treatment and daily physical activities. While pain is an inherently subjective experience, inadequate assessment can lead to undertreatment. In recent years, focus has shifted toward developing and utilizing self-reported pain in clinical practice and clinical trials [1316]. We propose that florio HAEMO can be used by people with hemophilia, their caregivers and physicians to better assess how, when and for how long reported pain interferes with daily life activities.
Wearable data are increasingly being used in clinical decision-making [17]. In our second questionnaire, 14 participants opted to test a wearable with the app. The reasons why the remaining 36 participants did not choose to test a wearable in part two of this survey are unknown. However, one possible explanation could be that some people may not consider themselves to be ‘tech savvy’ and may feel uncomfortable analyzing this novel data source [18]. Although the wearables were loaned to participants for the duration of this study, it is understandable that individuals from various socioeconomic backgrounds might view smartwatches as a non-essential item, potentially causing hesitation in borrowing one. In addition, some individuals with hemophilia, such as the elderly or less educated, may not have the capacity to understand how to use wearables [18]. Our survey also included young people and children who might not be familiar with using a wearable daily. Unsurprisingly, a recent qualitative survey of smartphone users among people with hypertension showed that younger age, higher income and higher education were key predictors for a higher level use of smartphone health apps [19]. Moreover, participants were able to recognize that self-monitoring of blood pressure could lead to empowerment in terms of their understanding of their condition and interactions with their general practitioners [19]. In our modern society, as the population continues to age, we should expect the proportion of people who consider themselves to be uncomfortable with such technologies is likely to decrease [18]. Among respondents who were engaged in testing a wearable in the second part of our survey, there was a numerically higher trend for data entry in the florio HAEMO app (e.g., for infusions and pain when indicated) but not for defining factor levels for future physical activity, suggesting that pairing the app to a wearable may be associated with increased motivation for data entry into the app. Of those who completed the second part of our survey, 66.0% indicated that they might consider or would prefer to use a wearable in the future with florio HAEMO, which is encouraging.
To the best of our knowledge, our survey is the first to evaluate the functionality of pairing a wearable with a hemophilia monitoring app. However, we acknowledge that the number of participants testing wearables is very small, and not all Central European countries were represented. Other limitations are similar to those identified for the first part of our survey, including the lack of standardized validity assessment for the questionnaire, no formal statistical comparison and self-reported study design, as described previously [2]. The flora HAEMO app currently does not support on-demand therapy or non-factor treatment. In addition, we cannot rule out selection bias of the treating physician when inviting participants to participate in the online survey. Therefore, the authors acknowledge that the results presented in this paper should be interpreted cautiously.

Conclusions

In summary, results from our follow-up questionnaire indicate that users of florio HAEMO maintain a high level of adherence to the smartphone app. Even after a more extended period of use, users find the app platform readily accessible and user-friendly, providing an easy-to-use solution for people with hemophilia and/or their caregivers on prophylactic treatment. In general, the concurrent use of a wearable device may be associated with increased motivation for data entry in the app. Furthermore, pairing a wearable in the future with the florio HAEMO app was considered a practical and/or preferable option for most participants who completed the study. Ultimately, our survey results suggest that the florio HAEMO hemophilia monitoring app is easy to use and appropriate for long-term use by people with hemophilia and/or their parents/caregivers. The option to pair the app with a wearable might also increase sports activity tracking, enable easier access to the app and provide more certainty about daily activities.

Acknowledgements

The authors thank all respondents and people with hemophilia and their parents/caregivers involved in the survey.

Medical Writing/Editorial Assistance

Medical writing and editorial assistance in preparing this manuscript were provided by Klara J. Belzar, PhD, and XLR8-Health, Hertfordshire, UK. Robert Antl from Seesame s.r.o., Slovakia, supported data analysis. Financial support for editorial and statistical assistance was provided by Sobi, the Czech Republic, in compliance with international guidelines for good publication practice.

Declarations

Conflict of Interest

Angelika Batorova received honoraria for consultancy and/or speaker fees and/or research funding from Grifols, Novo Nordisk, Octapharma, Pfizer, Sobi, and Takeda. Ana Boban received honoraria as an advisory board member and/or speaker fees from Amgen, AstraZeneca, Bayer, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Roche, Sobi, Swixx, and Takeda. Barbara Faganel Kotnik received honoraria for consultancy and/or speaker fees from Bayer, Licentis, Roche, Pfizer, Sobi, and Takeda. Ernest Bilic received honoraria for consultancy and/or speaker fees from Bayer, Octapharma, Novo Nordisk, Pfizer, Roche, and Sobi. Ester Zapotocka received honoraria for consultancy and/or speaker fees from Novo Nordisk, Pfizer, Roche, Sobi, and Takeda. Carmen Escuriola Ettingshausen received honoraria for consultancy and/or speakers fees from Bayer, Biomarin, CSL Behring, Florio HAEMO GmbH, Grifols, Kedrion, LFB, Octapharma, Roche/Chugai, Novo Nordisk, Pfizer, Sobi, and Shire/Takeda. Gediminas Puras is a current employee of Sobi. Radomira Hrdlickova received honoraria for consultancy and/or speaker fees from Bayer, Novo Nordisk, Octapharma, Pfizer, Roche, Sobi, and Takeda. Laszlo Nemes received honoraria for consultancy and/or speaker fees from Novo Nordisk, Sobi, Takeda, Roche, CSL Behring, and Bayer. Marianna Zombori received honoraria for consultancy and/or speaker fees from Bayer, CSL Behring, Octapharma, Novo Nordisk, Pfizer, Takeda, Octapharma, Kedrion, Novartis, Biotest, Sobi, and Roche. Pawel Laguna participated in clinical trials and received remuneration for lectures and consultations from Baxter, Takeda, Bayer Schering Pharma, CSL Behring, Biogen, Grifols, Novo Nordisk, Octapharma, Sobi, and Roche. Irena Preloznik Zupan and Jan Machal report no competing interests.

Ethical Approval

This study was conducted in compliance with European General Data Protection Regulation 2016/679, local legislation and Ethics Committee approval (University Hospital Bratislava Ethics Committee) in accordance with the Helsinki Declaration of 1964 and its later amendments. All participants provided informed consent for partaking in the study and any subsequent publication.
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by-nc/​4.​0/​.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Jetzt e.Med zum Sonderpreis bestellen!

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt bestellen und 100 € sparen!

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Jetzt bestellen und 100 € sparen!

e.Med Allgemeinmedizin

Kombi-Abonnement

Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.

Jetzt bestellen und 100 € sparen!

Anhänge

Supplementary Information

Below is the link to the electronic supplementary material.
Literatur
3.
Zurück zum Zitat Hay CRM, et al. The haemtrack home therapy reporting system: design, implementation, strengths and weaknesses: a report from UK Haemophilia Centre Doctors Organisation. Haemophilia. 2017;23(5):728–35.CrossRefPubMed Hay CRM, et al. The haemtrack home therapy reporting system: design, implementation, strengths and weaknesses: a report from UK Haemophilia Centre Doctors Organisation. Haemophilia. 2017;23(5):728–35.CrossRefPubMed
4.
Zurück zum Zitat Mondorf W, et al. Smart Medication ™, an electronic diary for surveillance of haemophilia home care and optimization of resource distribution. Hamostaseologie. 2019;39(4):339–46.CrossRefPubMed Mondorf W, et al. Smart Medication ™, an electronic diary for surveillance of haemophilia home care and optimization of resource distribution. Hamostaseologie. 2019;39(4):339–46.CrossRefPubMed
5.
Zurück zum Zitat Arvanitakis A, et al. A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa. Haemophilia. 2021;27(3):417–24.CrossRefPubMed Arvanitakis A, et al. A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa. Haemophilia. 2021;27(3):417–24.CrossRefPubMed
8.
Zurück zum Zitat Dodd C, et al. Wearable activity trackers in young people with haemophilia: what needs to be considered? Haemophilia. 2023;29(3):942–5.CrossRefPubMed Dodd C, et al. Wearable activity trackers in young people with haemophilia: what needs to be considered? Haemophilia. 2023;29(3):942–5.CrossRefPubMed
9.
Zurück zum Zitat Kang HS, et al. Wearing the future-wearables to empower users to take greater responsibility for their health and care: scoping review. JMIR Mhealth Uhealth. 2022;10(7): e35684.CrossRefPubMedPubMedCentral Kang HS, et al. Wearing the future-wearables to empower users to take greater responsibility for their health and care: scoping review. JMIR Mhealth Uhealth. 2022;10(7): e35684.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Khair K, et al. Self-management and skills acquisition in boys with haemophilia. Health Expect. 2015;18(5):1105–13.CrossRefPubMed Khair K, et al. Self-management and skills acquisition in boys with haemophilia. Health Expect. 2015;18(5):1105–13.CrossRefPubMed
11.
Zurück zum Zitat Dirzu N, et al. Mobile health technology for the personalized therapy of hemophilia. Front Med (Lausanne). 2021;8: 711973.CrossRefPubMed Dirzu N, et al. Mobile health technology for the personalized therapy of hemophilia. Front Med (Lausanne). 2021;8: 711973.CrossRefPubMed
13.
Zurück zum Zitat Boric K, et al. Outcome domains and pain outcome measures in randomized controlled trials of interventions for postoperative pain in children and adolescents. Eur J Pain. 2019;23(2):389–96.CrossRefPubMed Boric K, et al. Outcome domains and pain outcome measures in randomized controlled trials of interventions for postoperative pain in children and adolescents. Eur J Pain. 2019;23(2):389–96.CrossRefPubMed
14.
Zurück zum Zitat Dosenovic S, et al. Efficacy and safety outcome domains and outcome measures in systematic reviews of neuropathic pain conditions. Clin J Pain. 2018;34(7):674–84.CrossRefPubMed Dosenovic S, et al. Efficacy and safety outcome domains and outcome measures in systematic reviews of neuropathic pain conditions. Clin J Pain. 2018;34(7):674–84.CrossRefPubMed
15.
Zurück zum Zitat Pogatzki-Zahn E, et al. Patient-reported outcome measures for acute and chronic pain: current knowledge and future directions. Curr Opin Anaesthesiol. 2019;32(5):616–22.CrossRefPubMed Pogatzki-Zahn E, et al. Patient-reported outcome measures for acute and chronic pain: current knowledge and future directions. Curr Opin Anaesthesiol. 2019;32(5):616–22.CrossRefPubMed
16.
17.
Zurück zum Zitat Vijayan V, et al. Review of wearable devices and data collection considerations for connected health. Sensors (Basel). 2021;21(16):5589.CrossRefPubMed Vijayan V, et al. Review of wearable devices and data collection considerations for connected health. Sensors (Basel). 2021;21(16):5589.CrossRefPubMed
19.
Zurück zum Zitat Morrissey EC, et al. Smartphone apps for improving medication adherence in hypertension: patients’ perspectives. Patient Prefer Adherence. 2018;12:813–22.CrossRefPubMedPubMedCentral Morrissey EC, et al. Smartphone apps for improving medication adherence in hypertension: patients’ perspectives. Patient Prefer Adherence. 2018;12:813–22.CrossRefPubMedPubMedCentral
Metadaten
Titel
florio® HAEMO: A Longitudinal Survey of Patient Preference, Adherence and Wearable Functionality in Central Europe
verfasst von
Ester Zapotocka
Angelika Batorova
Ernest Bilic
Ana Boban
Carmen Escuriola Ettingshausen
Barbara Faganel Kotnik
Radomira Hrdlickova
Pawel Laguna
Jan Máchal
Laszlo Nemes
Irena Preloznik Zupan
Gediminas Puras
Marianna Zombori
Publikationsdatum
16.05.2024
Verlag
Springer Healthcare
Erschienen in
Advances in Therapy
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-024-02872-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.